News >

Expert Discusses Choice Between Immunotherapy and TKIs for HCC

Jason Harris
Published: Wednesday, May 31, 2017

Aiwu Ruth He, MD, PhD

Aiwu Ruth He, MD, PhD

Physicians treating hepatocellular carcinoma (HCC) often have to choose between a tyrosine kinase inhibitor (TKI) and immunotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication